Zymo Pharmaceuticals

Zymo Pharmaceuticals is a private biotechnology company focused on developing therapeutic products based on echogenic liposome drug-delivery technology. The company appears to be centered on translating ultrasound-responsive liposomal formulations from academic research into clinical products, including programs that encapsulate bioactive gases and small molecules. Publicly visible work associated with the company includes xenon-, nitric oxide-, and pioglitazone-loaded echogenic liposome approaches for vascular and neurologic indications such as vasospasm after subarachnoid hemorrhage and prevention of restenosis in peripheral arterial disease. Available evidence suggests the company remains at a preclinical stage, with limited public disclosure of a formal corporate pipeline or commercial product portfolio. Zymo Pharmaceuticals has been linked to inventors and researchers associated with the University of Texas Health Science Center at Houston and to intellectual property and trademark activity under the Zymo name.